Stock comparison
Harmony Biosciences Holdings
LeMaitre Vascular
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HRMY
Harmony Biosciences Holdings
Market cap
$1.75B
Sector
Healthcare
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HRMY | LMAT | Winner |
|---|---|---|---|
| Warren Buffett | 67B | 77B | LMAT |
| Benjamin Graham | 60C | 89A | LMAT |
| Philip Fisher | 75B | 81C | LMAT |
| Peter Lynch | 62C | 67B | LMAT |
| Joel Greenblatt | 28F | 56D | LMAT |
| Charlie Munger | 62C | 68D | LMAT |
| Terry Smith | 67B | 69D | LMAT |
Side-by-side metrics
| Metric | HRMY | LMAT |
|---|---|---|
| Market cap | $1.75B | $2.23B |
| P/E (TTM) | 11.8x | 37.1x |
| EV/EBIT | 6.4x | 36.6x |
| ROIC (TTM) | 12.5% | 9.43% |
| Gross margin | 76.55% | 72.39% |
| Net margin | 16.2% | 24.35% |
| Revenue CAGR 5y | 29.85% | 12.75% |
| EPS CAGR 5y | 46.45% | 19.04% |
| Debt / Equity | 0.2x | 0.5x |
| Dividend yield | 0.0% | 0.84% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HRMY leads on
- EV/EBIT6.4xvs 36.6x+82%
- P/E (TTM)11.8xvs 37.1x+68%
- EPS CAGR 5y46.45%vs 19.04%+59%
- Revenue CAGR 5y29.85%vs 12.75%+57%
LMAT leads on
- Dividend yield0.84%vs 0.0%+100%
- Net margin24.35%vs 16.2%+33%
- Market cap$2.23Bvs $1.75B+22%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.